Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Musculoskeletal Diseases

Blood and Lymph Conditions

Breast Neoplasms

Neoplasm Metastasis

Bone Neoplasms

Bone Marrow Diseases

Breast Diseases

Skin Diseases

Neoplastic Processes

Bone Diseases

Hematologic Diseases

All Drugs and Chemicals

Bone Density Conservation Agents

Endothelial Growth Factors

Mitogens

Zoledronic Acid

Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.

Weekly Zometa in combination with other antitumor agents one month after the initial dosing.

Zoledronic acid

Zometa 4 mg every four weeks (intravenous)

Xichun Hu, MD, PhD

The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be randomized into two groups.

The administration of Zometa in short intervals has been implied to be more potent in maximizing its antitumor and antiangiogenesis effects, while dosing every four weeks is an appropriate strategy for the prevention and management of bone metastases. This study was designed to explore the relationship between dosing of Zometa and level of circulating VEGF.

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases

Novartis

Fudan University

Xichun Hu/Dr.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis	NCT00524849	Metastatic Brea... Bone Metastases	Zoledronic acid Zoledronic acid	18 Years - 75 Years	Fudan University
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis	NCT00524849	Metastatic Brea... Bone Metastases	Zoledronic acid Zoledronic acid	18 Years - 75 Years	Fudan University

Spots Global Cancer Trial Database for circulating vegf